Dermatomyositis pathophysiology
|
Dermatomyositis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Dermatomyositis pathophysiology On the Web |
|
American Roentgen Ray Society Images of Dermatomyositis pathophysiology |
|
Risk calculators and risk factors for Dermatomyositis pathophysiology |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]
Overview
Pathophysiology
The diagnosis of dermatomyositis can be confirmed by muscle biopsy, EMG, and blood tests. It should be noted, however, that only muscle biopsy is truly diagnostic (pathognomic); liver enzymes and EMG are relatively non-specific. Liver enzymes, specificly creatine phosphokinase (CPK), are the major tool in assessing the progress of the disease and/or the efficacy of treatment. On the muscle biopsy, there are two classic microscopic findings of dermatomyositis. They are:
Dermatomyositis is associated with autoantibodies, especially anti-Jo1 antibody.[1]
Mechanism
The mechanism is conjectured to be complement-mediated damage of microscopic vessels with muscle atrophy and lymphocytic inflammation secondary to tissue ischemia.[2]
References
- ↑ Ghirardello, A (2006). "Clinical implications of autoantibody screening in patients with autoimmune myositis". Autoimmunity. 39 (3): 217–221. doi:10.1080/08916930600622645. PMID 16769655. Unknown parameter
|coauthors=ignored (help); Unknown parameter|month=ignored (help) - ↑ Benveniste, O (2004). "Pathogenesis of primary inflammatory myopathies". Presse Médicale. 33 (20): 1444–1450. doi:10.1016/S0755-4982(04)98952-X. PMID 15611679. Unknown parameter
|coauthors=ignored (help); Unknown parameter|month=ignored (help)